НЕБИДО. ПОЛНЫЙ ОБЗОР ТЕСТОСТЕРОН УНДЕКАНОАТ

Summary of the video

The speaker (Anton Ivashin) presents a “full review” of Nebido (testosterone undecanoate) and argues—based on scientific sources and his own clinical experience—that many claims made on Russian-language YouTube about Nebido are incorrect or inconsistent.

1) What “ideal” HRT means

• The goal of HRT is not to chase a specific testosterone number (like 15/20/35/40).
• Instead, it should use the minimum effective testosterone dose that improves clinical well-being and quality of life (energy, strength, absence of symptoms).

2) Why “half-life” matters (and why bloggers allegedly get it wrong)

He explains that half-life determines how to choose the injection interval.

• He criticizes common online figures for Nebido’s half-life (often around ~12–15 days, allegedly said by bloggers).
• He contrasts these with:
  • Official instructions mentioning a much longer figure (he states ~53 days and references drug behavior/peak pattern).
  • European/urologist recommendations stating ~34 days.
  • An older primary source (1998) suggesting even longer values (he cites ~21–23 days at certain doses, referencing how injections are discussed).

Conclusion (his view): misinformation about half-life leads people to apply wrong dosing intervals.

3) Critique of “official” dosing schedules vs clinical goals

• He doesn’t fully support how European/American associations recommend dosing (e.g., intervals like 10–14 weeks, or schemes using “loading”).
• His reasoning: those regimens may aim to keep testosterone above a lower threshold, rather than ensuring symptom control and stability.

4) Key pharmacodynamics: accumulation and peaks

He stresses two important effects:

• Accumulation with repeated injections (levels rise after several doses).
• A peak early after injection, which he links to side effects.

Key points:

• He claims the testosterone peak occurs around day 7–14 (supported by a study he mentions).
• During the peak, he says estradiol can also rise, which may cause:
  • nipple itching,
  • gynecomastia risk,
  • psycho-emotional changes,
  • sleep problems.

Therefore: therapy should be chosen based on clinical response, not lab numbers alone.

5) Clinical examples: same regimen, different results

He gives two patient examples to show why prescribing “the same scheme” for everyone is wrong:

• Patient A:

  • Injections every ~6 weeks
  • Testosterone curve rises strongly after injection, then declines
  • A dip to lower numbers occurred around mid-interval, but the patient still felt well, so the interval was considered optimal.

• Patient B:

  • Also ~1000 mg every ~6 weeks
  • His rise/decline pattern differed (lower/less dramatic peak and slower changes).

Takeaway: patients metabolize/respond differently, so interval and dosing must be individualized.

6) How he personally prescribes Nebido (typical approach)

• He says he generally doesn’t like Nebido, but it can work well for some patients.

Typical start:

• 1000 mg with a loading step: one injection, then another after one month.

After accumulation:

• He selects an individual interval based on:
  • symptoms and complaints,
  • approximate pre-injection testosterone level (he aims roughly ~20 nmol/L).

Common maintenance interval (his description):

• every ~6–8 weeks

If the patient can afford it (optional adjustment):

• He sometimes uses smaller doses (e.g., 500 mg every 3–4 weeks) to reduce high testosterone peaks and thereby reduce side effects.

7) Advantages and disadvantages (his view)

Advantages

• Injections are rare, which can improve stability.
• Lower tendency for extreme peaks compared with some other testosterone forms (he contrasts it with other injectables mentioned later).
• Often suitable for men needing fewer injections and for certain side-effect patterns.

Disadvantages / limitations

• The early peak period (first 1–2 weeks) can be harder to manage (estradiol/testosterone rise).
• Testosterone may drop later (around the 6th week), potentially bringing back symptoms of androgen deficiency if intervals are too long.
• Requires adjustments over time due to accumulation dynamics.
• He also mentions potential issues related to SHBG affecting symptom coverage (he says he has a separate video on SHBG).

8) Who Nebido is “for” (according to the speaker)

He frames Nebido as often preferable for older men (roughly 60–70+), especially when other testosterone regimens cause:

• cardiovascular-type concerns,
• higher peaks,
• increased hematocrit/blood viscosity (if the patient doesn’t want frequent hematocrit management),
• behavioral changes (aggression, anxiety, social disinhibition),
• elevated blood pressure,
• insomnia/sleep difficulties.

He suggests switching from other injectables (he names cypionate, enanthate, Omnadren) if side effects occur.

9) Closing idea

Overall message: Nebido therapy must be individualized using both clinical symptoms and lab trends, rather than blindly following YouTube claims or standard instructions.

---

Speakers (every speaker in the subtitles)

1. Anton Ivashin — urologist-andrologist, candidate of medical sciences; host/speaker